戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 refine current systems in obligate parasites go forward.
2 ariables does not permit Bell-type proofs to go forward.
3  GIA contaminate GRACE/GFO estimates as time goes forward.
4 mmendations and considerations for the field going forward.
5 research and clinical care in these patients going forward.
6 cipate will be central to work in this field going forward.
7 lypyrrole natural products and key analogues going forward.
8 velopment and set data collection priorities going forward.
9 r the sustainable use of tropical landscapes going forward.
10  as promising strategies and areas of growth going forward.
11 imately making a case for their expanded use going forward.
12 c risk factors for OFCs and various subtypes going forward.
13 ib predict even wider use of FLT3 inhibitors going forward.
14 ping new-onset diabetes or its complications going forward.
15  more systematic investigation of this field going forward.
16 iven cancer research strategies and planning going forward.
17 ecessity of more elaborate search strategies going forward.
18 bination monoclonal antibody efficacy trials going forward.
19  an important role in modelling human vision going forward.
20 nstream care use should be closely monitored going forward.
21 ountries will have to do more with much less going forward.
22 dictions and evaluate predictive performance going forward.
23 ysical studies of eEF2/ribosome interactions going forward.
24  to improve NbCS climate mitigation outcomes going forward.
25 ng these flexibilities into treatment policy going forward.
26 or reporting sex differences more thoroughly going forward.
27 rtebrae will be important a-priori knowledge going forward.
28 trategies we can take to mitigate challenges going forward.
29 mmercial cultivars to effectively manage PRR going forward.
30 ovartis's efforts to improve their programme going forward.
31 at remain in this exciting field of research going forward.
32 al standard in DNA research on human remains going forward.
33 uffering from micronutrient-driven disorders going forward.
34  address ethnicity-based health inequalities going forward.
35  into US policies on substance use treatment going forward.
36 HIV, intended to focus discussion and debate going forward.
37  be considered for risk assessments on MC-LR going forward.
38 her to get any new boosters/updated vaccines going forward.
39  virtual visits, and potential opportunities going forward.
40 ards further population mortality reductions going forward.
41 nd cancer modeling will influence each other going forward.
42 ns and identify challenges for chemogenetics going forward.
43 d by GWAS should be priorities for the field going forward.
44 ention with respect to the potential impacts going forward.
45 tiology, mechanism and preventive treatments going forward.
46 asures are preferred to reduce heterogeneity going forward.
47 e recovery of fertilizer N will be important going forward.
48 nt numbers and reassess abatement approaches going forward.
49 f the important challenges and opportunities going forward.
50 ation will continue to be an important focus going forward.
51 lar mechanistic focus that has great promise going forward.
52 t role for PRO assessment in phase II trials going forward.
53 a basic checklist our community might follow going forward.
54 d as EF to date, and what we wish to measure going forward.
55 ght areas of research that require our focus going forward.
56 ortance of studying commercialization policy going forward.
57 o guiding human decision-making and activity going forward.
58 RA, and what we can learn from these results going forward.
59                                              Going forward, a more interdisciplinary research approac
60                                              Going forward, an integrative approach is needed to addr
61                                              Going forward, anatomic pathologists will need to apply
62                               The challenges going forward are to distill from this complexity the un
63         We argue that ecotype should be used going forward as a significantly more accurate and appro
64  is needed in terms of regulating the sector going forward, as the role of for-profit providers canno
65 A diagonal approach should therefore be used going forward, blending disease-specific funding with sy
66 we describe how we might apply these lessons going forward, both during the ongoing COVID-19 pandemic
67                                              Going forward, both procedural and pharmacologic interve
68                                              Going forward, by connecting diverse stakeholders and pr
69 e tried-and-true modifications suggest that, going forward, chemists should take a bolder approach-re
70                                              Going forward, clamping the main renal artery appears un
71                                              Going forward, co-benefits modeling efforts should be ca
72         A total of 115 patients received the go-forward combination regimen.
73                                              Going forward, computational scaffold hopping is thought
74                                              Going forward, decoding has remarkable potential to asse
75                                          The go-forward dose is azacitidine 75 mg/m(2) on days 1 thro
76                                              Going forward, eventual social distancing orders and loc
77                              INTERPRETATION: Going forward, focus should be placed on scenarios that
78 bal implications for low-coverage areas and, going forward, for children.
79                                     In an on-going forward genetic screen, we identify the Drosophila
80                                              Going forward, identifying preoperative opioid use can i
81 ed to be considered for any pivotal research going forward if breath analysis is to provide robust va
82  biotin-streptavidin pair as a benchmark, we go forward in the demonstration of their unique sensitiv
83                                              Going forward, in order to better emulate the brain's fu
84                                Key questions going forward include how and how much new transposition
85 lished by these data, it is inescapable that going forward, investigators will operate under the hypo
86                          A critical question going forward is how these experiences have actually cha
87                  The most promising strategy going forward is through strong integration of multiple
88       Hence, one of the important challenges going forward is to find ways to pack MOFs efficiently w
89                                  A challenge going forward is to quantify the contributions of commun
90                                The challenge going forward is to uncover how the rosette orchestrates
91                                              Going forward, it is crucial to incorporate HT as a majo
92                                              Going forward, it is necessary to consolidate scattered
93                                              Going forward, it will be important to define the potent
94                                              Going forward, it will be important to determine whether
95                                              Going forward, it will be important to further elucidate
96                                              Going forward, it will be important to relate the altere
97                                       Hence, going forward, manufacturing thinner and highly selectiv
98 hat the most productive avenues for research going forward may be investigations into GAS in its 'nor
99                                              Going forward mitochondria-targeted Cas9 base editors wi
100 during the past century, and the projections going forward of what will happen if we do not act trans
101                                              Going forward, our findings have significant implication
102                                              Going forward, PFI-7 will be a valuable research tool fo
103                                              Going forward, PGHD will be used for patient-measured an
104                                              Going forward, policies toward sustainability have the p
105                                              Going forward, proactive welfare approaches are needed t
106                                              Going forward, prospective trials should enroll elderly
107          The combination was selected as the go-forward regimen for expansion.
108              Radiographic progression in the GO-FORWARD study was minimal in all treatment arms, prec
109                                       In the GO-FORWARD study, changes from baseline to week 24 (cont
110 ho entered early escape), and week 52 in the GO-FORWARD study.
111 toid Arthritis Despite Methotrexate Therapy [GO-FORWARD] study; n =444) were randomly assigned to rec
112                                              Going forward, systems that provide periodic surveillanc
113 es behind them, trial designs, and means for going forward that may impact favorably on progress.
114 ioned for the cutting-edge of human genomics going forward-that is, at 'The Forefront of Genomics'.
115                                              Going forward, the big questions concern the degree to w
116                                              Going forward, the combination of traditional culturing
117                                              Going forward, the main challenge will be ensuring that
118                                              Going forward, the structures will be critically importa
119                                              Going forwards, the study highlights the need for future
120                                              Going forward, these plasma escape maps can inform surve
121                                              Going forward, these proteomic datasets will serve as va
122                                              Going forward, this model will serve as a tool to invest
123                                              Going forward, this work can directly support the develo
124                                              Going forward, this work now provides a basis for strate
125 s of the protein boost can allow researchers going forward to design vaccines that generate responses
126 ifferences, and how they are being addressed going forward to optimize reporting of CT and MRI findin
127                                              Going forward, transient LTREs will enhance understandin
128                                              Going forward, we aim to launch a community initiative t
129                                              Going forward, we believe that collaborative efforts sup
130                                              Going forward, we believe that the use of penumbral imag
131                                              Going forward, we believe that this model represents a f
132                                              Going forward, we believe that this unified model can of
133                                              Going forward, we expect activators to play important ro
134                                              Going forward, we expect future mechanistic insights and
135                                              Going forward, we foresee a paradigm shift from individu
136            In order to support the community going forward, we have developed OLS4, implementing the
137                                              Going forward, we hope this will help provide support to
138                                              Going forward, we offer lessons learned from our collect
139                                              Going forward, we strive to improve the coverage and con
140                                              Going forward, well-defined policy direction will be nec
141 oaches to funding and equitable distribution going forward, which includes embedding human rights int
142 und Fe-hydride with a proton forming H(2) or going forward with N(2) binding coupled to the reductive

 
Page Top